February 25, 2022 11:16 AM ESTUpdated 03:36 PM
R&D

Russ­ian in­va­sion of Ukraine threat­ens hun­dreds of clin­i­cal tri­als

Paul Schloesser

Associate Editor

Day 2 of the Russ­ian in­va­sion has brought head­lines of a bat­tle for the na­tion’s cap­i­tal, signs that mil­lions of Ukraini­ans may be­come refugees and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times